公开(公告)号：US10370682B2

公开(公告)日：2019-08-06

申请号：US15315539

申请日：2015-06-25

Applicant: NOVOZYMES A/S

Inventor： Brian R. Scott ,  Mark David Wogulis ,  Sven Pedersen ,  James Lavigne

IPC: C12P19/14 ,  C12N9/24 ,  C12P19/34 ,  C12P21/06 ,  C12N1/20 ,  C12P7/10 ,  C12N15/52 ,  C12N15/82

Abstract: The present invention relates to xylanase variants, comprising an alteration at least at one position corresponding to position 87 of the polypeptide of SEQ ID NO: 3, wherein the variant has xylanase activity and has increased xylanase inhibitor tolerance compared to the xylanase of SEQ ID NO: 3; and i) wherein the variant has at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, but less than 100% sequence identity to the polypeptide of SEQ ID NO: 3; or ii) wherein the number of alterations is 1-20, e.g., 1-10 such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 alterations. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.

公开(公告)号：US11891637B2

公开(公告)日：2024-02-06

申请号：US17714461

申请日：2022-04-06

Applicant: Novozymes A/S

Inventor： Janine Lin ,  Doreen Bohan ,  Michelle Maranta ,  Leslie Beresford ,  Michael Lamsa ,  Matt Sweeney ,  Mark David Wogulis ,  Elizabeth Znameroski ,  Frank Winther Rasmussen

IPC: C12N9/24 ,  C12P19/02 ,  C12P19/14 ,  C12N9/42 ,  C12N9/02 ,  D21C5/00 ,  D21H17/00 ,  C11D3/386

CPC classification number: C12N9/2437 ,  C11D3/38645 ,  C12N9/0071 ,  C12N9/2434 ,  C12P19/02 ,  C12P19/14 ,  C12Y302/01021 ,  D21C5/005 ,  D21H17/005 ,  C12P2203/00 ,  C12Y114/00 ,  C12Y302/01004

Abstract: The present invention relates to GH61 polypeptide variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.

公开(公告)号：US20240110169A1

公开(公告)日：2024-04-04

申请号：US18524366

申请日：2023-11-30

Applicant: Novozymes A/S ,  Novozymes, Inc.

Inventor： Janine Lin ,  Doreen Bohan ,  Michelle Maranta ,  Leslie Beresford ,  Michael Lamsa ,  Matt Sweeney ,  Mark David Wogulis ,  Elizabeth Znameroski ,  Frank Winther Rasmussen

IPC: C12N9/42 ,  C11D3/386 ,  C12N9/02 ,  C12P19/02 ,  C12P19/14 ,  D21C5/00 ,  D21H17/00

CPC classification number: C12N9/2437 ,  C11D3/38645 ,  C12N9/0071 ,  C12N9/2434 ,  C12P19/02 ,  C12P19/14 ,  C12Y302/01021 ,  D21C5/005 ,  D21H17/005 ,  C12P2203/00 ,  C12Y114/00 ,  C12Y302/01004

Abstract: The present invention relates to GH61 polypeptide variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.

公开(公告)号：US20170096687A1

公开(公告)日：2017-04-06

申请号：US15315539

申请日：2015-06-25

Applicant: NOVOZYMES A/S

Inventor： Brian R. Scott ,  Mark David Wogulis ,  Sven Pedersen ,  James Lavigne

IPC: C12P7/10 ,  C12N15/52 ,  C12N15/82 ,  C12N9/24

CPC classification number: C12P7/10 ,  C12N9/2402 ,  C12N9/248 ,  C12N9/2482 ,  C12N15/52 ,  C12N15/8257 ,  C12Y302/01008 ,  C12Y302/01037 ,  Y02E50/16

Abstract: The present invention relates to xylanase variants, comprising an alteration at least at one position corresponding to position 87 of the polypeptide of SEQ ID NO: 3, wherein the variant has xylanase activity and has increased xylanase inhibitor tolerance compared to the xylanase of SEQ ID NO: 3; and i) wherein the variant has at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, but less than 100% sequence identity to the polypeptide of SEQ ID NO: 3; or ii) wherein the number of alterations is 1-20, e.g., 1-10 such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 alterations. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.